Drug intelligence / Profile preview

mAb_Staph

Development stage: Preclinical
Lead developer: Immunethep
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

mAb_Staph is a monoclonal antibody (IgG1) in development by Immunethep for the treatment of Staphylococcus infections, including Staphylococcus aureus (including methicillin-resistant S. aureus [MRSA] and vancomycin-resistant S. aureus [VRSA]) and Staphylococcus epidermidis. The antibody targets bacterial glyceraldehyde-3-phosphate dehydrogenase (bGAPDH), a conserved virulence factor excreted by bacteria to suppress the host's immune system. By neutralizing extracellular bGAPDH, mAb_Staph prevents the activation of Toll-like receptor 2 (TLR2) on B lymphocytes and the subsequent rapid production of Interleukin-10 (IL-10), thereby restoring the host's natural immune response to clear the bacterial infection.

Targets

GAPDH (Glyceraldehyde-3-phosphate dehydrogenase)

Beyond the preview

Go deeper on mAb_Staph.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mAb_Staph.

Explore the full profile